1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

In development [GID-TA11007] Expected publication date: TBC

  • Project information
  • Project documents

28726-Navitoclax-Ruxolitinib-for-Myelofibrosis-V1.0-FEB2022-NON-CONF.pdf (nihr.ac.uk)